Lifting weights isn't vanity, it’s life insurance. Strength training cuts risks of all‑cause death by ~17%.

RT @Dr_Singularity: If we can’t make more young people, we need to stay young longer - aging reversal is the key. Aging reversal R&D must….

Speeding causes nearly one-third of all traffic deaths. It’s no game. Learn about the dangers of driving too fast.

RT @Dr_Singularity: The era of reversing aging at the cellular level is beginning. A biotech company called Life Biosciences is working on….

Belmonte said that Altos Labs wants to apply the partial reprogramming strategy to rejuvenate organs that are currently not suitable for transplantation.

Partial reprogramming was the subject of multiple talks at the meeting, both scientific and translational. Juan Carlos Izpisua Belmonte at Altos Labs, described his team’s work on using partial reprogramming to prevent what they call “mesenchymal drift.”.

Make America Fentanyl Free supports President Trump’s efforts to end the fentanyl crisis.

There are currently “no regenerative therapeutics for glaucoma and no therapeutics at all for NAION,” Life Biosciences chief scientific officer Sharon Rosenzweig-Lipson told the audience at the ARDD meeting.

The underlying technology was licensed by Harvard Med School to Life Biosciences Inc., which has been developing it for open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), a form of sudden-onset vision loss.

Researchers demonstrated that expressing OSK in vivo in retinal ganglion cells restored older cells to a more youthful state in terms of their methylation patterns, promoted axon regeneration after injury, and reversed age-related vision loss and vision loss due to glaucoma.

The 2020 discovery that expressing only three of the Yamanaka factors �� Oct, Sox and Klf (OSK) – could rejuvenate cells without returning them to a pluripotent state turned in vivo reprogramming into a clinical possibility.

New @BioWorld article -.Life Bio is developing epigenetic reprogramming technology for liver disease, not just optic neuropathies. ER-100 will enter trials 2026, making it the first use of partial epigenetic reprogramming in humans

Ultra-processed food intake is associated with higher mortality. The strong-willed resist the easy path.

This is more than just four quarters. It’s every tailgate, every chant, every moment. It’s fuel that goes beyond the field. This is CELSIUS!.LIVE. FIT. GO.

Well said 💯.

I'm optimistic: so far the epigenetic rejuvenation technology headed to human trials in January regenerates tissues in general, no matter which organ or how it's damaged, whether by injury, disease or time.

Jerry McLaughlin, our CEO, and I are so grateful for the creativity, dedication, and persistence the board and entire R&D team led by Sharon Rosenzweig-Lipson

Zohran Mamdani: He votes for activists, not you

This is an exciting moment for @lifebiosciences and for all of us who believe in the potential of cellular rejuvenation

Epigenetic reprogramming in vivo is now shown to work across systems, from liver to eye, and likely many more.

With ER-100 on track for human trials in Q1 2026, this program is moving quickly toward patients 💉👁️

This adds to earlier data showing clear functional benefits in the eye. They also beautifully match the mouse data we published in Nature (2020), in fact they are even more dramatic in their reversal of DNA methylation 😲

In ocular diseases, ER-100, the drug candidate from from our lab and first in development @lifebiosciences, showed a remarkable ability to restore healthy DNA methylation patterns and boost neuronal regeneration processes in a nonhuman primate model

New (old) age mediations.

These results add to the weight of evidence that reprogramming is not just for age-reversal, it can be used to treat diseases that affect millions worldwide and with few effective treatments